DUBLIN, July 14, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/spl8ft/europe_markets) has announced the addition of the "Europe Markets for Hyaluronic Acid Viscosupplementation 2011-2021" report to their offering.
Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan that is naturally present in the human body. It is mainly concentrated in fluids in the joints. Its function is to provide cushioning for joints.
Individuals who suffer from osteoarthritis are deficient in these fluids. One of the treatment options for these patients is HA viscosupplementation injections.
Much like the BGS market, the HA market has been experiencing price erosion due to an increase in competition, especially in the German market; the price for a five-injection product in Germany had been reduced to a mere 60 for all five syringes. ASPs for all three cycle products are expected to decline mildly over the forecast period.
Key Topics Covered:
1. Research Methodology
1.1 Research Scope
1.2 9-Step Methodology
2. Country Profiles 2.1 Introduction 2.2 Germany 2.3 France 2.4 United Kingdom 2.5 Italy 2.6 Spain 2.7 Benelux 2.8 Scandinavia 2.9 Austria 2.10 Switzerland 2.11 Portugal
3. Hyaluronic Acid Viscosupplementation Market
3.1 Introduction 3.2 Market Overview 3.3 Market Analysis And Forecast 3.3.1 Total Hyaluronic Acid Viscosupplementation Market 3.3.2 Single-Injection Market 3.3.3 Three-Injection Market 3.3.4 Five-Injection Market 3.4 Drivers And Limiters 3.4.1 Market Drivers 3.4.2 Market Limiters 3.5 Competitive Analysis
- Croma-Pharma - Fidia - Laboratoire Genevrier - Meda Pharma - Recordati - Sanofi - Seikagaku - Smith & Nephew - TRB Chemedica - Tedec Meiji
For more information visit http://www.researchandmarkets.com/research/spl8ft/europe_markets
Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets